Targeting Ctdnep1-Deficient Brain Tumors

Ctdnep1-deficient Tumors cells were subcutaneously injected into eight-week-old female athymic BALB/c nude mice or NSG mice. Tumors will be harvested after 6–10 weeks and quantified. 1 × 10⁵ NPCs in a 5 μl with 2 μl matrigel were stereotactically injected into the NSG mouse cerebellum. Animals were monitored weekly and euthanized when they showed signs of brain tumor. The mouse brain tissue with tumor was embedded in paraffin and sectioned at a thickness of 5 μm for H/E and immunohistochemistry assays. Ctdnep1 cKO tumors exhibit the large cell/anaplastic morphology observed in MYC-driven Group 3 MB, which was confirmed by a neuropathologist Dr. Christina Fuller. The NSG mice with Ctdnep1-cKO NPC tumors in the cerebellum were randomized into different groups and administered Prexasertib (15 mg/kg) and/or JQ1 (50 mg/kg) or vehicle (10% DMSO in 10% HP-β-Cyclodextrin, Sigma) on alternating days via intraperitoneal injection for 14 days^{64 (link)}.